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Abstract
Background: Several studies have shown that variants in the glucokinase regulatory protein gene (GCKR) were
associated with type 2 diabetes and dyslipidemia. The purpose of this study was to examine whether tag single
nucleotide polymorphisms (SNPs) in the GCKR region were associated with type 2 diabetes and related traits in a
Han Chinese population and to identify the potential mechanisms underlying these associations.
Methods: We investigated the association of polymorphisms in the GCKR gene with type 2 diabetes by employing
a case-control study design (1118 cases and 1161 controls). Four tag SNPs (rs8179206, rs2293572, rs3817588 and
rs780094) with pairwise r
2 > 0.8 and minor allele frequency > 0.05 across the GCKR gene and its flanking regions
were studied and haplotypes were constructed. Genotyping was performed by matrix-assisted laser desorption/
ionization time-of-flight mass spectroscopy using a MassARRAY platform.
Results: The G alleles of GCKR rs3817588 and rs780094 were associated with an increased risk of type 2 diabetes
after adjustment for year of birth, sex and BMI (OR = 1.24, 95% CI 1.08-1.43, p = 0.002 and OR = 1.22, 95% CI 1.07-
1.38, p = 0.002, respectively). In the non-diabetic controls, the GG carriers of rs3817588 and rs780094 were
nominally associated with a lower plasma triglyceride level compared to the AA carriers after adjustment for year
of birth, sex and BMI (p for trend = 0.00004 and 0.03, respectively). Furthermore, the association of rs3817588 with
plasma triglyceride level was still significant after correcting for multiple testing.
Conclusions: The rs3817588 A/G polymorphism of the GCKR gene was associated with type 2 diabetes and plasma
triglyceride level in the Han Chinese population.
Background
Glucokinase (GCK) is the key glucose phosphorylation
enzyme responsible for the first rate-limiting step in the
glycolysis pathway. GCK regulates glucose metabolism
in the liver and glucose-stimulated insulin secretion
from pancreatic beta cells [1]. GCK activity is closely
regulated by the glucokinase regulatory protein (GCKR),
a process depending on fructose 6-phosphate and fruc-
tose 1-phosphate [2,3]. Gckr-deficient mice display
reduced GCK protein levels and activity in the liver and
exhibit impaired postprandial glycemic control [4,5]. In
a previous study, adenoviral-mediated hepatic overex-
pression of GCKR significantly improved insulin
sensitivity and glucose tolerance in mice and resulted in
decreased leptin concentration and increased triglyceride
levels [6].
In the Diabetes Genetics Initiative genome-wide asso-
ciation study, the GCKR rs780094 A allele was found to
be strongly associated with hypertriglyceridemia in
populations from Finland and Sweden [7]. Subsequently,
a large study of Danish white participants confirmed
that the rs780094 A allele was associated with increased
fasting triglycerides, impaired fasting and OGTT-related
insulin release, reduced homeostasis model assessment
of insulin resistance (HOMA-IR), increased risk of dysli-
pidemia and a modestly decreased risk of type 2 dia-
betes [8]. The HapMap II CEU data http://www.
hapmap.org showed that rs780094 was in strong linkage
disequilibrium (LD) (r
2 = 0.932) with a non-synonymous
GCKR variant (Pro446Leu, rs1260326). The DESIR
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variant rs1260326 T allele was strongly associated with
increased triglyceride levels, lower fasting glucose and
insulin levels, a lower HOMA-IR index, and a higher
risk for dyslipidemia, but a lower risk for hyperglycemia
and type 2 diabetes in a general French population [9].
Another study, combining data from 12 independent
cohorts comprising more than 45,000 individuals with
various ethnic backgrounds, confirmed that GCKR
rs780094 and rs1260326 were strongly associated with
opposite effects on fasting plasma triglyceride and glu-
cose concentrations [10]. Recently, the MAGIC study
conducted a large-scale meta-analysis and provided con-
vincing evidence that the GCKR rs780094 A allele was
associated with lower fasting glucose and insulin levels,
a lower HOMA-IR index, a higher triglyceride level, and
a lower risk for type 2 diabetes [11].
Several studies of the association of GCKR variants
with type 2 diabetes or glucose homeostasis parameters
in Chinese populations have been reported [12-14]. In a
study of a population-based sample of Han Chinese
individuals, the GCKR rs780094 A allele was found to
be significantly associated with a reduced risk of
impaired fasting glucose (IFG) and type 2 diabetes,
decreased fasting glucose, increased homeostasis model
assessment of beta cell function (HOMA-B), and fasting
triglyceride levels; GCKR rs1260326 displayed similar
associations [12]. A study of healthy Chinese adults and
adolescents showed that the GCKR rs780094 A allele
was associated with increased triglyceride levels, and
GCKR rs780094 alone did not contribute to fasting glu-
cose but interacted with GCK rs1799884 to increase
fasting glucose [13]. However, another study in a Han
Chinese cohort did not find any association between
GCKR rs780094 and type 2 diabetes [14]. Therefore, the
association of GCKR variants with fasting plasma glu-
cose and type 2 diabetes is still not confirmed in a Chi-
nese population. The aim of this study was to replicate
the associations of GCKR variants with type 2 diabetes
and related traits found in Caucasian populations in a
Han Chinese population and to identify the potential
mechanisms underlying these associations.
Methods
Study population
All participants were of Southern Han Chinese ancestry
and resided in the Shanghai metropolitan area. We
recruited 1118 unrelated type 2 diabetic inpatients from
the Endocrinology and Metabolism Department of
Zhongshan Hospital, Fudan University, Shanghai, China.
All diabetic patients met the 1999 WHO criteria for dia-
betes [15], had been diagnosed after the age of 29 years,
and were treated with oral hypoglycemic agents and/or
insulin. The 1161 unrelated non-diabetic control
participants were recruited from people undergoing
health examinations in Zhongshan Hospital, were older
than 40 years, and had a fasting plasma glucose < 5.6
mmol/l.
Written informed consent was obtained from all parti-
cipants and the study was approved by the ethnic com-
mittee of Zhongshan Hospital, Fudan University,
Shanghai, China.
Clinical measurements
Both the diabetic patients and the controls were exten-
sively phenotyped for anthropometric and biochemical
traits related to glucose metabolism. The phenotypes
assessed in our study include height, weight, waist cir-
cumference, blood pressure, fasting glucose, total choles-
terol, triglyceride, high density lipoprotein cholesterol
(HDL-C), and low density lipoprotein cholesterol (LDL-
C). BMI was calculated as weight (kg)/height
2 (m
2). In a
subgroup of diabetic patients (n = 664), potential beta
cell function was determined using intravenous arginine
stimulation tests under fasting conditions. After taking a
baseline blood sample, a 10% (wt/vol.) solution of argi-
nine hydrochloride (5 g) was injected intravenously for
30-45 s. The end of the injection period was designated
as time zero, after which samples were taken at 2, 4 and
6 min. The acute insulin response (AIR) to arginine was
calculated as the mean of the insulin levels in the post-
injection samples minus the insulin level in the presti-
mulus sample. The acute C-peptide response (ACPR) to
arginine was calculated in the same way using sampled
C-peptide levels.
Genotyping
We selected tag single nucleotide polymorphisms (SNPs)
across the region of the GCKR gene (include 20 kb
upstream and 9 kb downstream of the gene) from the
HapMap Phase II, using the pairwise tagging model.
The pairwise tagging algorithm was developed by
Carlson et al. and has been described previously [16].
In brief, the algorithm is based on the r
2 LD statistic
and is comprised of several steps [16]. Starting with all
SNPs above the specified minor allele frequency
(MAF) threshold in the candidate gene region, the sin-
gle SNP exceeding the specified r
2 threshold with the
maximum number of other SNPs above the MAF
threshold is identified [16]. This maximally informative
SNP and all associated SNPs are grouped as a bin of
associated sites [16]. Any SNP exceeding the threshold
r
2 with all other SNPs in the bin is specified as a tag
S N Pf o rt h eb i n[ 1 6 ] .T h u s ,o n eo rm o r eS N P sw i t h i n
a bin are specified as “tag SNPs” and only one tag SNP
would need to be genotyped per bin. The binning pro-
cess is iterated, analyzing all as-yet-unbinned SNPs at
each round, until all sites exceeding the MAF
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mative set of common SNPs (tag SNPs) is selected and
is to be assayed in candidate gene association studies
[16]. All polymorphisms above a specified frequency
threshold either are directly assayed or exceed a speci-
fied threshold level of r
2 with an assayed polymorph-
ism (tag SNP) [16].
The selection criteria used in our study were an r
2 >
0.8 and a minor allele frequency > 0.05. Finally, four tag
SNPs (rs8179206, rs2293572, rs3817588 and rs780094)
were selected and genotyped. The genotyping was per-
formed by matrix-assisted laser desorption/ionization
time-of-flight mass spectroscopy using a MassARRAY
platform (MassARRAY Compact Analyzer, Sequenom,
San Diego, CA, USA).
Statistical analysis
Continuous variables are expressed as the means ±
SEM. Comparisons between groups were performed
with T testing and c
2 testing for normally distributed
continuous and categorical variables, respectively. Devia-
tions from the Hardy-Weinberg equilibrium were
assessed by means of c
2 testing. SNPs that were not in
Hardy-Weinberg equilibrium were excluded from
further analysis. Pairwise linkage disequilibrium includ-
ing D’ and r
2 was estimated using Haploview. Haplo-
types estimating from the population genotype data
were performed in Haplo. Stats (R2.8.1). We did allelic
analysis for the association of GCKR polymorphisms
with type 2 diabetes using logistic regression. We did
genotypic analysis for the association of GCKR poly-
morphisms with quantitative traits using a general linear
model, assuming an additive model. We tested the asso-
ciation of haplotypes with type 2 diabetes and quantita-
tive traits by using logistic regression and a general
linear model. Non-normally distributed values were log-
transformed before analysis. All models were adjusted
for year of birth and sex. Additional models were
adjusted for BMI. Analysis was performed using SPSS
software version 13.0. We used Bonferroni correction
for multiple testing.
Results
Baseline characteristics
The baseline characteristics of participants in this study
are presented in Table 1. Of 2279 participants, 1118
were type 2 diabetes patients and 1161 were non-dia-
betic controls. Diabetic cases were older and had higher
BMI, waist circumference, fasting glucose and triglycer-
ide levels, but lower cholesterol concentrations than
non-diabetic controls. There was no significant differ-
ence in the distribution of sex between diabetic cases
and non-diabetic controls (p = 0.34).
Associations of GCKR polymorphisms with type 2
diabetes
Overall, four SNPs (rs8179206, rs2293572, rs3817588
and rs780094) were selected and genotyped in the pre-
sent study. The call rates of rs8179206, rs2293572,
rs3817588 and rs780094 were 98.5%, 98.0%, 96.6% and
98.5%, respectively. The concordant rates of all SNPs
based on 120 duplicates were 100%.
Rs8179206, rs2293572, rs3817588 and rs780094 were
in Hardy-Weinberg equilibrium in the total population,
diabetic cases and non-diabetic controls (Table 2). The
G allele of rs3817588 was significantly associated with
an increased risk of type 2 diabetes after adjustment for
year of birth and sex (OR = 1.21, 95% CI 1.06-1.39, p =
0.004) (Table 3). In addition, the G allele of rs780094
was significantly associated with an increased risk of
type 2 diabetes after adjustment for year of birth and
sex (OR = 1.19, 95% CI 1.05-1.34, p = 0.005) (Table 3).
Table 1 Baseline characteristics of all genotyped participants, diabetic cases and non-diabetic controls
Characteristic All participants
(n = 2279)
Diabetic cases
(n = 1118)
Non-diabetic controls
(n = 1161)
P value*
Age (years) 58.3 ± 0.24 60.2 ± 0.37 56.5 ± 0.32 < 0.001
Men (%) 43.6 44.6 42.7 0.34
BMI (kg/m
2) 24.0 ± 0.07 24.4 ± 0.11 23.5 ± 0.09 < 0.001
Waist circumference (cm) 85.6 ± 0.45 90.5 ± 0.81 80.5 ± 0.28 < 0.001
Fasting glucose (mmol/l) 6.30 ± 0.01 8.17 ± 0.04 4.86 ± 0.01 < 0.001
Total cholesterol (mmol/l)
+ 4.76 ± 0.03 4.43 ± 0.04 5.10 ± 0.03 < 0.001
Triglyceride (mmol/l)
+ 1.54 ± 0.02 1.64 ± 0.03 1.46 ± 0.02 < 0.001
HDL-C (mmol/l)
+ 1.24 ± 0.01 1.16 ± 0.01 1.32 ± 0.01 < 0.001
LDL-C (mmol/l)
+ 2.69 ± 0.02 2.40 ± 0.03 3.00 ± 0.02 < 0.001
Systolic BP (mmol/l) 126.8 ± 0.38 134.2 ± 0.53 119.4 ± 0.45 < 0.001
Diastolic BP (mmol/l) 79.4 ± 0.19 80.7 ± 0.28 78.0 ± 0.26 < 0.001
Continuous data are expressed as the means ± SEM
+Variables were log-transformed before statistical analysis; numbers in the table were back-transformed
*p value for comparison between cases and controls
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adjustment for BMI (Table 3). The associations of
rs8179206 and rs2293572 with type 2 diabetes were not
significant (OR = 1.18, 95% CI 0.85-1.65, p = 0.32 and
OR = 1.04, 95% CI 0.88-1.23, p = 0.64, respectively)
(Table 3).
Associations of GCKR polymorphisms with quantitative
traits in non-diabetic controls
In the non-diabetic controls, the GG and AG carriers of
rs3817588 were nominally associated with a lower
plasma triglyceride level compared with the AA carriers
after adjustment for year of birth, sex and BMI (p =
0.0003 and p = 0.02, respectively), and the trend was in
the same direction (p for trend = 0.00004) (Table 4).
The association of rs3817588 with plasma triglyceride
level was still significant after correction for multiple
testing. The GG carriers of rs780094 were nominally
associated with a lower plasma triglyceride level com-
pared with the AA carriers, after adjustment for year of
birth, sex and BMI (p = 0.01), and the trend was in the
same direction (p for trend = 0.03) (Table 4). However,
the association of rs780094 with plasma triglyceride
level was not significant after correction for multiple
testing. The associations of rs8179206 and rs2293572
with plasma triglyceride level were not significant (Table
4). The GG carriers of rs3817588 were nominally asso-
ciated with a higher waist circumference compared with
the AA carriers, after adjustment for year of birth and
sex (p = 0.01), and the trend was in the same direction
(p for trend = 0.04) (Table 4). The association was not
significant after correction for multiple testing. The
associations of other polymorphisms with waist circum-
f e r e n c ew e r en o ts i g n i f i c a n t( T a b l e4 ) .N o n eo ft h ef o u r
polymorphisms showed a significant association with
BMI, fasting plasma glucose, total cholesterol, HDL-C,
LDL-C, systolic blood pressure or diastolic blood pres-
sure (Table 4).
Associations of GCKR polymorphisms with AIR and ACPR
in diabetic cases
A subgroup of diabetic cases (n = 664) was classified
into 4 groups according to the duration of diabetes. The
range of diabetes duration was 1 month to 40 years in
this subgroup of diabetic patients. In the third quartile
subgroup with a diabetic duration of 8-11 years, the GG
carriers of rs780094 were nominally associated with
lower levels of AIR and ACPR compared with the AA
carriers, after adjustment for year of birth, sex and BMI
(p = 0.02 and 0.03, respectively), and the trend was in
Table 2 Characteristics of SNPs genotyped in GCKR
SNP identification Chromosome
Position
Relation to
the gene
Major
allele
Minor
allele
MAF HWE P value
1 rs8179206 22573946 Exon A G 0.03 0.76
2 rs2293572 27582281 Intron G C 0.14 0.85
3 rs3817588 27584716 Intron A G 0.30 0.10
4 rs780094 27594741 Intron A G 0.45 0.90
Table 3 Allelic distribution of GCKR polymorphisms and association with type 2 diabetes
Alleles Non-DM (%) DM (%) Odds Ratio1
a 95% CI P value Odds Ratio2
b 95% CI P value
rs8179206
A 97.0 96.6 1 (Ref.) 1 (Ref.)
G 3.0 3.4 1.18 0.85-1.65 0.32 1.29 0.91-1.82 0.15
rs2293572
G 85.9 85.6 1 (Ref.) 1 (Ref.)
C 14.1 14.4 1.04 0.88-1.23 0.64 1.04 0.88-1.24 0.64
rs3817588
A 72.1 68.0 1 (Ref.) 1 (Ref.)
G 27.9 32.0 1.21 1.06-1.39 0.004* 1.24 1.08-1.43 0.002*
rs780094
A 56.6 52.6 1 (Ref.) 1 (Ref.)
G 43.4 47.4 1.19 1.05-1.34 0.005* 1.22 1.07-1.38 0.002*
a Adjusted for year of birth and sex
b Adjusted for year of birth, sex and BMI
*Significant after Bonferroni correction (p < 0.0125 (0.05/4) was the corrected statistically significant level in association analysis between the individual SNP and
type 2 diabetes)
The major allele was used as a reference when comparing the risk of diabetes between alleles.
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n BMI (kg/m
2) Waist circumference
(cm)
Fasting glucose
(mmol/l)
Total cholesterol*
(mmol/l)
Triglyceride*
(mmol/l)
HDL-C*
(mmol/l)
LDL-C*
(mmol/l)
Systolic BP
(mmHg)
Diastolic BP
(mmHg)
rs8179206
AA 1076 23.50 ± 0.09 80.50 ± 0.29 4.86 ± 0.01 5.11 ± 0.03 1.45 ± 0.02 1.32 ± 0.01 3.01 ± 0.03 119.14 ± 0.46 77.95 ± 0.27
AG 68 23.33 ± 0.39 81.48 ± 1.23 4.86 ± 0.05 5.04 ± 0.11 1.52 ± 0.09 1.30 ± 0.03 2.95 ± 0.10 122.28 ± 1.99 79.55 ± 1.11
GG
$ 2 19.47 ± / 68.00 ± / 4.10 ± / 3.80 ± / 0.90 ± / 1.16 ± / 2.23 ± / 110.00 ± / 70.00 ± /
P value
a# 0.36 0.33 0.19 0.27 0.51 0.61 0.53 0.45 0.76
P value
b# 0.15 0.31 0.49 0.24 0.64 0.35 0.72
rs2293572
GG 842 23.53 ± 0.10 80.60 ± 0.32 4.85 ± 0.01 5.09 ± 0.03 1.44 ± 0.02 1.32 ± 0.01 3.00 ± 0.03 119.32 ± 0.53 78.13 ± 0.31
GC 276 23.37 ± 0.17 80.22 ± 0.58 4.87 ± 0.02 5.16 ± 0.06 1.51 ± 0.04 1.31 ± 0.02 3.03 ± 0.05 118.96 ± 0.90 77.54 ± 0.50
CC 23 24.03 ± 0.53 80.00 ± 1.85 4.98 ± 0.06 5.39 ± 0.19 1.53 ± 0.15 1.39 ± 0.06 3.12 ± 0.17 121.24 ± 1.95 78.96 ± 1.29
P value
a# 0.48 0.63 0.18 0.17 0.28 0.54 0.74 0.14 0.24
P value
b# 0.14 0.17 0.15 0.37 0.73 0.19 0.44
rs3817588
AA 598 23.35 ± 0.12 79.88 ± 0.40 4.85 ± 0.02 5.13 ± 0.04 1.50 ± 0.03 1.32 ± 0.01 3.02 ± 0.04 119.27 ± 0.66 77.79 ± 0.38
AG 423 23.52 ± 0.15 81.14 ± 0.47 4.87 ± 0.02 5.08 ± 0.05 1.41 ± 0.03 1.33 ± 0.02 3.00 ± 0.04 118.93 ± 0.76 78.12 ± 0.45
GG 103 23.97 ± 0.30 82.13 ± 1.01 4.84 ± 0.04 4.99 ± 0.10 1.26 ± 0.05 1.32 ± 0.03 2.95 ± 0.08 119.58 ± 1.68 77.77 ± 0.94
P value
a# 0.15 0.04 0.84 0.35 0.001
& 0.78 0.82 0.59 0.76
P value
b# 0.81 0.29 0.00004
& 0.70 0.84 0.39 0.63
rs780094
AA 368 23.22 ± 0.16 79.66 ± 0.50 4.84 ± 0.02 5.12 ± 0.05 1.49 ± 0.04 1.32 ± 0.02 3.02 ± 0.05 119.13 ± 0.87 77.83 ± 0.50
AG 558 23.59 ± 0.13 80.80 ± 0.42 4.86 ± 0.02 5.13 ± 0.04 1.44 ± 0.03 1.32 ± 0.01 3.02 ± 0.04 119.73 ± 0.70 78.40 ± 0.39
GG 218 23.67 ± 0.20 81.34 ± 0.70 4.85 ± 0.03 5.00 ± 0.07 1.35 ± 0.04 1.32 ± 0.02 2.92 ± 0.06 119.15 ± 1.04 77.33 ± 0.62
P value
a# 0.15 0.16 0.74 0.32 0.06 0.79 0.40 0.96 0.24
P value
b# 0.63 0.31 0.03 0.30 0.43 0.99 0.18
Data are expressed as the means ± SEM
a Adjusted for year of birth and sex
b Adjusted for year of birth, sex and BMI
* Variables were log-transformed before statistical analysis; numbers in the table were back-transformed
# p for trend
$ This group had too few subjects and no SEM was calculated
&Significant after Bonferroni correction (p < 0.0014 (0.05/36) was the corrected statistically significant level in association analysis between the individual SNP and quantitative traits in the control group)
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9the same direction (p for trend = 0.03 and 0.09, respec-
tively) (Figure 1). In the fourth quartile subgroup with a
diabetic duration over 11 years, the GG carriers of
rs3817588 were nominally associated with lower levels
of AIR and ACPR compared with the AA carriers, after
adjustment for year of birth, sex and BMI (p = 0.008
and 0.01, respectively), and the trend was in the same
direction (p for trend = 0.03 and 0.03, respectively) (Fig-
ure 1). However, these associations were no longer sig-
nificant after correction for multiple testing.
Associations of GCKR haplotypes with type 2 diabetes
The haplotype block was constructed for the four SNPs
(rs8179206, rs2293572, rs3817588 and rs780094) in
GCKR. All four SNPs fell into one block (Additional file
1, Figure S1). The block was associated with type 2 dia-
betes after adjustment for year of birth and sex (the glo-
bal p value = 2.7 × 10
-5) (Additional file 1, Table S1).
The haplotypes AGGG and GGGG were associated with
an increased risk of type 2 diabetes (OR = 1.18, 95% CI
1.02-1.37, p = 0.02 and OR = 2.08, 95% CI 1.60-2.71, p
=5 . 9×1 0
-8, respectively) (Additional file 1, Table S1).
The associations remained similar after additional
adjustment for BMI (Additional file 1, Table S1).
Associations of GCKR haplotypes with quantitative traits
in non-diabetic controls
In the non-diabetic controls, the haplotype block was
nominally associated with plasma triglyceride level
adjusted for year of birth, sex and BMI (the global p
value = 0.0001) (Additional file 1, Table S2). The haplo-
type AGGG was associated with a lower plasma trigly-
ceride level adjusted for year of birth, sex and BMI (p =
2.2 × 10
-5). The association remained significant after
correction for multiple testing. BMI, waist circumfer-
ence, fasting plasma glucose, total cholesterol, HDL-C,
LDL-C, systolic blood pressure and diastolic blood pres-
sure were not significantly different between haplotypes
(Additional file 1, Table S2).
Discussion
In line with previous studies, our study confirmed the
opposite effects of GCKR variants on glucose and trigly-
ceride concentrations. Our data showed that the GCKR
rs780094 G allele and rs3817588 G allele were asso-
ciated with an increased risk of type 2 diabetes in Han
Chinese individuals. The G alleles were also nominally
associated with a lower fasting triglyceride level. More-
over, the association of rs3817588 with fasting triglycer-
ide level was still significant after correction for multiple
testing. The associations of GCKR rs780094 with type 2
diabetes and triglyceride level have been replicated in
many studies of different ethnic populations since the
Diabetes Genetics Initiative genome-wide association
study [7-11]. Our study confirmed this association again
in a Han Chinese population. Our study was the first
study which adopted a tagging strategy and selected tag
SNPs of GCKR including 20 kb upstream and 9 kb
downstream of the gene for studying. We demonstrated
that another polymorphism rs3817588 in GCKR affected
glucose and lipid metabolism in a similar way as
rs780094, which was not reported in the previous
studies.
In the present study, the G allele of GCKR rs780094
was associated with higher odds of type 2 diabetes (OR
= 1.19). The effect size was similar to that observed in
another study of a Han Chinese population [12]. In the
studies of populations of European descent, the G allele
of rs780094 was also associated with a higher odds of
diabetes, but the effect size was much smaller (OR =
1.06-1.08) [8,10,11]. The frequency of the rs780094 G
allele is substantially lower in Han Chinese (43%) than
in White Europeans (65%). The difference in genetic
background between different ethnic groups may explain
the discrepancy between effect sizes in Han Chinese and
European populations. The G allele of GCKR rs3817588
was associated with higher odds of type 2 diabetes (OR
= 1.21). For both polymorphisms, the G risk alleles for
diabetes were nominally associated with a lower trigly-
ceride level. The mechanism by which the GCKR var-
iants lead to type 2 diabetes and protect against
dyslipidemia remains to be determined. A potential
explanation is that GCK regulation by GCKR is altered
in the liver, which leads indirectly to decreased GCK
activity [17]. Decreased GCK activity was associated
with decreased glucose utilization in the liver [17]. With
decreased glucose utilization and glycolytic flux, GCK,
phosphofructokinase, and fatty acid synthase are down-
regulated, whereas phosphoenolpyruvate carboxykinase
and glucose-6-phosphatase are upregulated [17]. These
changes increase hepatic glucose output, lower malonyl-
CoA concentration and inhibit de novo lipogenesis and
VLDL triglyceride production [17].
We next investigated whether the GCKR variants were
associated with beta cell function as determined by an
arginine stimulation test in diabetic patients. We found
that in groups with a relatively long diabetic duration,
GCKR variants were associated with AIR and ACPR.
The carriers of the G alleles of rs780094 and rs3817588
had lower values for AIR and ACPR than the AA homo-
zygotes. These findings suggested that the GCKR var-
iants probably contribute to diabetes susceptibility by
impairing beta cell function, although the associations of
the GCKR variants with AIR and ACPR became non-
significant after correction for multiple testing. A study
in a Han Chinese population found that rs780094 was
associated with beta cell function as estimated by
HOMA-B, which was consistent with our findings [12].
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SNPs exhibited moderate to strong LD in terms of D’
and fell into one block. The block was associated with
type 2 diabetes after adjustment for year of birth, sex
and BMI. The AGGG haplotype and the GGGG haplo-
type were associated with an increased risk of type 2
diabetes. Both haplotypes carried the G risk alleles of
rs3817588 and rs780094. However, the ACAG haplotype
which carried the G risk allele of rs780094 did not show
any association with type 2 diabetes. This would suggest
that the effect of the rs780094 G allele on the risk of
type 2 diabetes was due to its LD with rs3817588. The
difference of the AGGG haplotype and the GGGG hap-
lotype was at the locus of rs8179206. However, the
GGGG haplotype was associated with a 2.08 times risk
of diabetes which was much higher than that of the
AGGG haplotype (OR = 1.18), suggesting that the G
alleles of rs8179206 and rs3817588 had synergistic effect
on the development of type 2 diabetes. Rs8179206 G
allele also contributed to the risk of type 2 diabetes
although it was not associated with diabetes in single
locus analysis.
Rs3817588 and rs780094 are located in introns of
GCKR. Based on the current data, we cannot confirm
whether they are in the splicing site or the transcrip-
tion factor binding site of the gene. We therefore
assume them to be linked with one or more functional
variants within the GCKR gene or its regulatory
regions. Rs780094 is tightly linked with rs1260326
(HapMap CEU r
2 = 0.93, CHB r
2 = 0.82), a non-synon-
ymous variant in GCKR associated with type 2 diabetes
and triglyceride level [9,10,12]. A functional study
showed that GCKR rs1260326 was associated with fast-
ing plasma glucose and triglyceride levels, and this
effect was mediated through regulating the activity of
GCK in liver [17]. We did not genotype rs1260326 in
t h ec u r r e n ts t u d yb e c a u s eo ft h ef a c tt h a ti ti si n
strong LD with rs780094 and represents the same
information as rs780094, which was demonstrated by a
p r e v i o u ss t u d yi naH a nC h i n e s ep o p u l a t i o n[ 1 2 ] .
Although there is no evidence that rs3817588 is linked
with any functional variant now, future fine mapping
and resequencing of the GCKR gene may detect such
functional variants.
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Figure 1 Acute insulin response (AIR) and acute C-peptide response (ACPR) stratified according to GCKR rs780094 or rs3817588
genotypes by quartile of diabetic duration. * p < 0.05 compared with homozygote of major allele (AA) ** p < 0.01 compared with
homozygote of major allele (AA) # p for trend < 0.05 All p values were not significant after Bonferroni correction (p < 0.0016 (0.05/32) was used
as Bonferroni corrected statistically significant level in association analysis between the individual SNP and AIR or ACPR) The figures below the
genotypes indicate the number of diabetic cases for each genotype group.
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Page 7 of 9Our study had some limitations. Firstly, we did not
investigate gene-environment interactions. Because both
genetic variants and environmental factors contribute to
type 2 diabetes, and adverse environmental factors
(high-caloric diets, physical inactivity, etc.) have impor-
tant influence on the development of diabetes, the eluci-
dation of gene-environment interactions should not be
overlooked in future studies. Secondly, we did not do a
functional study of rs3817588. Further functional study
is needed to determine whether rs3817588 is associated
with selective splicing of mRNA or the binding of tran-
scription factors and affects expression level of protein
ultimately.
Conclusions
We demonstrated that the rs3817588 A/G polymorph-
ism of the GCKR gene was associated with type 2 dia-
betes and plasma triglyceride level in the Han Chinese
population.
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